Treating cancer by targeting a weakness.
Brody
Lawrence C
LC
Genome Technology Branch of the National Human Genome Research Institute, National Institutes of Health, Bethesda, Md, USA.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D004249:DNA Damage; D004260:DNA Repair; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C499321:Parp1 protein, mouse; D000071137:Poly (ADP-Ribose) Polymerase-1